Results 121 to 130 of about 2,198 (193)

RET Fusion Testing in Patients With NSCLC: The RETING Study [PDF]

Introduction: RET inhibitors with impressive overall response rates are now available for patients with NSCLC, yet the identi fication of RET fusions remains a dif ficult challenge. Most guidelines encourage the upfront use of next -generation sequencing
Abdulkader, Ihab, Alonso, Marta, Aranda, Ignacio, Arriola, Edurne, Baixeras, Nuria, Benito, Amparo, Calles, Antonio, Caminoa, Alejandra, Cebollero, Maria, Clavé, Sergi, Compañ, Desamparados, Conde, Esther, Curto, Daniel, De Castro, Javier, Dómine Gómez, Manuel, Esteban-Rodriguez, Isabel, Felip, Enriqueta, Garcia-Gonzalez, Jorge, Garrido, Pilar, Hernandez, Susana, Insa, Amelia, Jimenez, Beatriz, Juan-Vidal, Oscar, Lopez-Rios, Fernando, López Vilaró, Laura, Majem, Margarita, Mancheño, Nuria, Martin, Paloma, Martinez, Rebeca, Massuti, Bartomeu, Nadal, Ernest, Palanca, Sarai, Paz-Ares, Luis, Provencio, Mariano, Reguart, Noemi, Rodriguez Carrillo, Jose Luis, Rojo, Federico, Salas, Clara, Sansano, Irene, Teixidó, Cristina, Universitat Autònoma de Barcelona   +40 more
core   +2 more sources

Genomically matched therapy in advanced solid tumors: the randomized phase 2 ROME trial [PDF]

: Despite recent advancements demonstrating the potential of tumor-agnostic biomarkers to guide effective therapies, randomized evidence supporting the clinical superiority of precision oncology approaches compared to standard therapies remains limited ...
Adamo, Vincenzo, Aglietta, Massimo, Ascierto, Paolo Antonio, Bengala, Carmelo, Berardi, Rossana, Biffoni, Mauro, Blandino, Giovanni, Bonanno, Laura, Bordonaro, Roberto, Botticelli, Andrea, Bracarda, Sergio, Buffoni, Lucio, Butturini, Giovanni, Capoluongo, Ettore, Cappuzzo, Federico, Ceracchi, Maurizio, Cerbelli, Bruna, Conte, Pierfranco, Cremolini, Chiara, Crimini, Edoardo, Curigliano, Giuseppe, D'Amati, Giulia, Damiano, Paola, De Giorgi, Ugo, DeCensi, Andrea, Del Mastro, Lucia, Fabbri, Agnese, Fenocchio, Elisabetta, Fornaro, Lorenzo, Giannini, Giuseppe, Gori, Stefania, Guarneri, Valentina, Lombardi, Giuseppe, Lonardi, Sara, Maiello, Evaristo, Malapelle, Umberto, Mannozzi, Francesca, Marchetti, Paolo, Marino, Donatella, Martini, Nello, Masi, Gianluca, Mazzuca, Federica, Metro, Giulio, Mucciarini, Claudia, null, null, Nuti, Marianna, Pessino, Annamaria, Piancastelli, Alessandra, Pinto, Carmine, Pisegna, Simona, Pozzessere, Daniele, Pruneri, Giancarlo, Puglisi, Fabio, Quaresmini, Davide, Russo, Antonio, Savarese, Antonella, Scagnoli, Simone, Simmaco, Maurizio, Strigari, Lidia, Tagliaferri, Pierosandro, Tamberi, Stefano, Tonini, Giuseppe, Tosoni, Alicia, Urbini, Benedetta, Vanella, Vito, Verkhovskaia, Sofia, Zaffignani, Elena, Zambelli, Alberto   +67 more
core   +1 more source

LIBRETTO-431: Confirming the Superiority of Selpercatinib to Chemotherapy and the Lack of Efficacy of Immune Checkpoint Inhibitors in Advanced RET Fusion-Positive (RET+) NSCLC, Another Unique Never-Smoker Predominant Molecular Subtype of NSCLC

Lung Cancer: Targets and Therapy
Alexandria TM Lee,1 Sai-Hong Ignatius Ou2 1Department of Medicine, University of California Irvine School of Medicine, Orange, CA, 92868, USA; 2Chao Family Comprehensive Cancer Center, Orange, CA, 92868, USACorrespondence: Sai-Hong Ignatius Ou ...
Lee ATM, Ou SI
doaj  

Significant response to pralsetinib in a medullary thyroid cancer harboring double RET variants of unknown significance [PDF]

, 2022
S. Hescot, Julien Masliah‐Planchon, Pauline du Rusquec, Célia Dupain, Maud Kamal, Vincent Servois, Ivan Bièche   +6 more
openalex   +1 more source

Exposure‐Response Relationships for Pralsetinib in Patients with RET‐Altered Thyroid Cancer or RET Fusion‐Positive Nonsmall Cell Lung Cancer [PDF]

Nastya Kassir, David McDougall, Denison Kuruvilla, Sean Kim, Shaun S. Kumar, Ahmadur Rahman, Thorsten Ruf, Sravanthi Cheeti, Wendy Ankrom   +8 more
openalex   +1 more source

Quantitative bioanalytical assay for the selective RET inhibitors selpercatinib and pralsetinib in mouse plasma and tissue homogenates using liquid chromatography-tandem mass spectrometry

, 2020
Rahime Şentürk, Yaogeng Wang, Alfred H. Schinkel, Jos H. Beijnen, Rolf W. Sparidans   +4 more
openalex   +1 more source

Targeted Therapy in NSCLC: A Comprehensive Review of Molecular Drivers and Treatment Strategies [PDF]

Non-small cell lung cancer (NSCLC) remains a leading cause of cancer-related mortality worldwide, with its management increasingly guided by molecular profiling and targeted therapies.
Kasianik , Viktoryia, Kiełbaszewska , Iga, Kowalczuk , Dmytro, Lazitskaya , Darya, Milasheuskaya, Valeryia, Miraniuk, Katsiaryna, Myrnyi , Andrii, Sobchynskyi , Mykola, Surosz , Natalia, Turlej , Kamil, Wiczkowski , Dawid   +10 more
core   +1 more source

RET 898-901Del mutant, a variant of unknown significance, has a durable response to Pralsetinib in a Medullary Thyroid Carcinoma patient [PDF]

, 2023
Patrick Conway, Dmytro B. Kovalskyy, Marco A. Alanis, Amy Mumbower, Kayla E. Chamberlin, Daruka Mahadevan   +5 more
openalex   +1 more source

A novel germline deletion of p.C630 in RET causes FMTC and promotes cell proliferation and sensitivity to pralsetinib ：Supplementary Table 1.

, 2022
Xiao Ma, Xiuli Ma, Lihan Qin, Zhen Zhu, Haibo Han   +4 more
openalex   +1 more source

ABCB1 and ABCG2, but not CYP3A4 limit oral availability and brain accumulation of the RET inhibitor pralsetinib

, 2021
Yaogeng Wang, Rolf W. Sparidans, Sander Potters, Maria C. Lebre, Jos H. Beijnen, Alfred H. Schinkel   +5 more
openalex   +2 more sources